Patent · US Active

Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide

US10759758B2 · kind B2 · utility

16Cited by

6References

10Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Tobias Thaler · Neunburg vorm Wald, DE
Johannes Platzek · Berlin, DE
Nicolas Guimond · Wuppertal, DE

Key dates

Filing date	Apr 25, 2017
Grant date	Sep 1, 2020
Priority date	—
Expiry date	Apr 25, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to crystalline forms of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.